Biest Cream for Menopause: What's Actually in It, What It Costs, and When It's the Right Choice
Before you choose compounded Bi-Est
Use the evidence and label checks below to clarify whether you need an FDA-approved estradiol product, a documented compounded preparation, or an in-person evaluation first.
Affiliate disclosure: this page contains compensated links to some HRT providers. Commission never decides which option we tell you to choose, and it did not soften a single finding below. We publish material limitations even when the company pays us.
Biest cream for menopause is a prescription compounded blend of estriol (E3) and estradiol (E2). No Bi-Est product is FDA-approved, and FDA says no approved U.S. drug contains estriol. For most women, FDA-approved estradiol is the evidence-first starting point; Bi-Est fits when a documented need requires compounding. (FDA)
That's the short answer. Now here's the part almost nobody tells you.
What changes that answer: whether an approved product contains an ingredient you cannot use · whether you need a dosage form that is not commercially available · whether your symptoms need systemic or local treatment · whether you have a uterus · your state and payment method · and—this one catches people—whether the “BiEST” you're looking at requires a prescription at all. Some products sold under that exact name do not.
And one more thing, which is the reason this page exists. The ratio on your prescription tells you almost nothing on its own. Two women can both say they're on “Bi-Est 2.5” and be applying very different amounts of estradiol. We did the arithmetic and built the label check below. It takes about ninety seconds to compare with your own dispensing label.
Bi-Est may be worth discussing if:
- You have a documented allergy or reaction to an active ingredient or excipient in an FDA-approved product.
- You need a dosage form an FDA-approved product does not provide.
- A licensed clinician can explain the specific medical reason the custom preparation is needed.
- You understand that the finished cream is compounded and not FDA-approved.
- You know the exact formula, pharmacy, follow-up plan, and—if you have a uterus—the endometrial-protection plan.
Ask about something else first if:
- You chose Bi-Est because someone said it is more natural, gentler, safer, or better absorbed than FDA-approved estradiol.
- You want standardized dosing and FDA-reviewed prescribing information.
- Insurance coverage matters to you.
- Your only symptoms are vaginal dryness, burning, urinary symptoms, or painful sex—that is usually a different treatment path.
- Nobody has explained why an FDA-approved estradiol patch, gel, spray, tablet, or local vaginal product would not meet your need.
Start with an in-person clinician—not only an online form—if:
- You have unexplained bleeding after menopause.
- You have a personal history of breast, uterine, or another estrogen-sensitive cancer and need individualized specialist guidance.
- You have a history of blood clots, stroke, heart attack, or significant liver disease.
- You have new symptoms that may require an examination, imaging, or urgent testing.
- You are pregnant or might be pregnant.
This is not a complete eligibility list. It is the set of situations where a product-selection page should not make the decision for you.
Biest cream in 30 seconds
| Question | Verified answer |
|---|---|
| What is it? | A custom-compounded mixture of estriol (E3) and estradiol (E2) |
| Is the finished product FDA-approved? | No |
| Is any estriol drug FDA-approved in the U.S.? | No |
| Can it be lawfully compounded? | Yes, when federal and state compounding conditions are met, including the applicable patient-specific prescription requirements |
| Common ratios | 80/20 and 50/50; the label must show which hormone comes first |
| Does the ratio tell you the dose? | No—you also need concentration, amount dispensed per pump or click, prescribed amount, and route |
| Current telehealth pricing checked | Published programs range from $51 to $249 per month before some first-month charges, with major differences in membership, prepayment, and enrollment status |
| Insurance | Most Bi-Est programs checked are cash-pay; HSA/FSA acceptance and reimbursement are plan-specific |
| Prescription required? | Yes for patient-specific compounded Bi-Est. A nonprescription product is a different regulatory category |
| Evidence-first starting point | FDA-approved estradiol unless a documented need makes compounding necessary |
The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.
The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.
What we actually verified
We read the public seller pages used in the price and formula tables on August 31, 2026. We checked FDA's estriol language, the National Library of Medicine's DailyMed label repository, the federal OTC hormone-cream rule, the randomized Bi-Est pharmacokinetic trial, the 2023 compounded-estradiol exposure study, and current guidance from ACOG, the Endocrine Society, the National Academies, The Menopause Society, and the British Menopause Society.
What we did not do: we did not take these medications, purchase a program, complete a clinician consult, assay a cream, or test a dispenser. We can verify what a public page or label says. We cannot tell you what is physically in a tube we never tested, and we will not pretend otherwise.
Where a seller's statement conflicts with a regulatory or clinical source, we show the conflict. Provider-stated is not the same as independently established.
This follows The HRT Index Verification Standard: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule—top providers monthly, full roster quarterly. Every provider is assessed on the same five pillars, in this order: clinical legitimacy, care quality, medication fit, price transparency, access. It is not a numeric score and we do not assign one.
Still unresolved, and labeled where it matters: Winona's public mg/g strength, container size, and milligrams per pump · several providers' exact state eligibility before intake · checkout totals where public pages do not show every required charge · the physical contents of every product discussed.
1. What is Bi-Est cream, and what is it used for?
Bi-Est is not one standardized medicine. It is a patient-specific compounded preparation containing estriol and estradiol in a ratio and strength selected by a prescriber. A body cream may be prescribed for systemic menopause symptoms, while a vaginal formula serves a different route and goal; concentration, base, dispenser, and directions can vary.
“Bi-Est” means two estrogens. That's it. No mystery in the name.
Your body produces three major estrogens. Estradiol (E2) is the principal estrogen during the reproductive years and the hormone used in many FDA-approved menopause medicines. Estriol (E3) is a less potent estrogen that rises substantially during pregnancy. Estrone (E1) becomes the predominant circulating estrogen after menopause. Bi-Est combines estriol and estradiol. A compounded mixture that adds estrone is commonly called Tri-Est.
“Bioidentical” and “compounded” are two different words
This is the single most useful distinction on the page, and it is the distinction much of the market blurs.
Bioidentical describes a hormone with the same chemical structure as a hormone produced by the body. Compounded describes how a pharmacy prepares a medication for an individual prescription rather than a manufacturer producing an FDA-approved, standardized drug product.
Those are not the same thing. FDA-approved estradiol products come as patches, gels, sprays, tablets, vaginal creams, inserts, and rings. FDA-approved micronized progesterone and prasterone are also structurally identical to hormones or hormone precursors found in the body.
So you do not have to choose between “bioidentical” and “FDA-approved.” You can have both.
What you cannot get in an FDA-approved U.S. drug is estriol. FDA states that no approved U.S. drug contains estriol. That is why a U.S. product containing estriol is outside the FDA-approved lane. (FDA)
Why “my Bi-Est dose” is not a dose until you know five things
A single number on a prescription does not describe what you are applying. You need all five:
- 1. Ingredient order — does 80/20 mean estriol:estradiol or estradiol:estriol?
- 2. Ratio — 80/20, 50/50, or another split.
- 3. Concentration — milligrams per gram (mg/g), milligrams per milliliter (mg/mL), or another clearly defined unit.
- 4. Delivered amount — grams or milliliters per pump, click, or measured application.
- 5. Route — body skin, vaginal, or another route stated on the dispensing label.
Miss one and you cannot reliably calculate the amount of each hormone applied.
One thing to rule out right now
If your symptoms are only vaginal dryness, burning, urinary symptoms, or pain during sex—with no hot flashes or night sweats—you may be looking at the wrong category of treatment. FDA-approved low-dose vaginal estrogen is a local path with its own evidence, dosing, and safety questions. Start with the vaginal estrogen guide instead →
2. Is Biest cream for menopause FDA-approved?
No. No Bi-Est finished product is FDA-approved, and FDA says no approved U.S. drug contains estriol. A patient-specific estriol compound may be prepared under federal and state compounding rules, but FDA does not review the finished cream for safety, effectiveness, quality, or consistent strength before it reaches the patient. (FDA)
FDA's current consumer language is direct: there are no FDA-approved drugs containing estriol, marketed estriol drugs are compounded and unapproved, and FDA does not have evidence that estriol-containing drugs are safer forms of estrogen.
Why it can still be lawfully compounded
Section 503A of the Federal Food, Drug, and Cosmetic Act creates conditions under which a state-licensed pharmacist or physician may compound a patient-specific medication. A bulk drug substance's USP or National Formulary monograph can be one part of that pathway, but it is not a blanket approval. The individual prescription, ingredient eligibility, pharmacy practice, state law, and other statutory conditions still matter. (FDA compounding Q&A)
The accurate sentence is not “Bi-Est is legal.” It is:
A patient-specific Bi-Est prescription can be lawfully compounded when the applicable federal and state requirements are met.
Four phrases that sound like approval and are not
| Phrase on a seller page | What it can honestly mean | What it does not mean |
|---|---|---|
| “USP-grade ingredients” | A raw ingredient is represented as meeting a compendial standard | The finished cream is FDA-approved |
| “From an FDA-registered facility” | A facility has a registration relationship with FDA | FDA reviewed, endorsed, or approved the product |
| “State-licensed compounding pharmacy” | The pharmacy holds a state license | Each custom formula was FDA-reviewed |
| “503A compounded prescription” | It is prepared for an identified patient under the applicable compounding pathway | Approved, interchangeable, or established as equivalent to an FDA-approved drug |
There is a fifth version on several current seller pages: “the active ingredients are FDA-approved.” Estradiol appears in FDA-approved products. Estriol does not. An ingredient's sourcing label does not turn the final compound into an approved drug—and the statement is not accurate when it includes estriol as an FDA-approved active ingredient.
There are two different things sold as “BiEST cream”
This is the finding most likely to save someone from buying the wrong category.
DailyMed—the National Library of Medicine's public repository of submitted drug labeling—currently displays a label for 3.6OZ BIEST 2.5 ESTROGEN CREAM, NDC 82018-0030-6, from Shyne Brands/BIOLabs PRO. The record classifies it as a human OTC drug label and an unapproved drug. The labeling says it contains estriol and estradiol in an 80:20 ratio, makes a temporary hot-flash-relief claim, and also says “For external cosmetic use only.” (DailyMed)
An NDC number or DailyMed listing does not mean FDA approval. DailyMed reproduces submitted labeling; the record itself carries the unapproved-drug disclaimer.
The same DailyMed record gives two different quantity descriptions
| Where the number appears | Estriol | Estradiol |
|---|---|---|
| Drug Facts percentages | 0.2% = 2 mg/g | 0.05% = 0.5 mg/g |
| Amount implied for a 102 g bottle | 204 mg | 51 mg |
| Structured ingredient table | 2 mg in 102 g | 0.5 mg in 102 g |
| Difference between the bottle totals | 102× | 102× |
We are not saying the physical product is under-dosed or over-dosed. We did not test it, and the package image also says each dose delivers 2,000 micrograms of estriol and 500 micrograms of estradiol—figures consistent with a 2.5 mg total dose. The point is narrower and stronger: the public record contains internally inconsistent denominator information, so the structured table cannot be used as a reliable bottle-content calculation.
That is not a reason to speculate about what is in a bottle. It is a reason not to treat a public OTC label as a substitute for a patient-specific prescription and dispensing label.
Why the nonprescription version is a different category, legally
21 CFR 310.530 addresses topically applied hormone-containing OTC drug products and names estrogens. The rule says this class lacks adequate data to be generally recognized as safe and effective for OTC use and can be subject to regulatory action when marketed outside applicable requirements. (21 CFR 310.530)
We are stating the rule and the record. We are not alleging that a named company committed a violation or that FDA has taken enforcement action against it.
The one-second test
If a licensed prescriber does not have to approve it for you, it is not patient-specific compounded Bi-Est. Do not treat the nonprescription product as a cheaper version of the prescription category.
3. Is estriol safer, gentler, or better than estradiol?
Estriol is commonly described as a less potent estrogen than estradiol, but lower potency is not proof of lower clinical risk. FDA says it does not have evidence that estriol-containing drugs are safe and effective or are safer forms of estrogen, and major medical organizations do not endorse compounded estriol as a safer upgrade from FDA-approved estradiol. (FDA)
You'll see the softer language everywhere: gentler. Kinder. Protective. More natural. Skin-friendly.
Some of it starts with a real pharmacologic distinction. The problem is the jump from less potent to less risky. That second claim needs comparative outcomes evidence. The current Bi-Est evidence base does not provide it.
Provider-stated claims versus what the evidence can support
| Current public claim pattern | What the public evidence supports |
|---|---|
| “Both active ingredients are FDA-approved” | Estradiol appears in approved drugs; no approved U.S. drug contains estriol |
| “Estriol makes the blend gentler or safer” | FDA says it lacks evidence that estriol-containing drugs are safer forms of estrogen |
| “Custom ratio means personalized precision” | A custom ratio can be prescribed, but ratio alone does not establish absorption, clinical effect, or an ideal dose |
| “Cream provides superior or steady absorption” | The small direct Bi-Est trial did not establish superiority; lower cream exposure occurred at two tested strengths, with substantial variation |
| “Bioidentical means natural and therefore safer” | Molecular identity does not establish approval, purity, consistency, or comparative safety |
This is the honest position: estriol is biologically active. That does not create U.S. FDA approval, establish that a particular compound is consistent, or show that adding estriol makes systemic menopause therapy safer.
The sale is often built around the estriol. The evidence still has to earn the claims made for it.
4. What do Bi-Est 80/20 and 50/50 actually mean?
The ratio describes the split between estriol and estradiol. It does not tell you the cream's total concentration, how much one pump delivers, what amount you apply, or how much is absorbed. At the same total concentration and the same ingredient order, 50/50 contains 2.5 times as much estradiol as 80/20.
Let's take this apart, because once you see it you cannot unsee it.
First: which number is which?
“80/20” is meaningless until the label states the ingredient order. Current U.S. pharmacy and provider pages commonly write the ratio as estriol:estradiol, making 80/20 equal to 80% estriol and 20% estradiol. That convention is not a guarantee.
If your dispensing label says only “80/20,” ask the pharmacist to write out the ingredient order. You cannot check anything else until that is settled.
Second: ratio and concentration are different numbers
A label reading Bi-Est E3:E2 80/20, 2.5 mg/g means there are 2.5 milligrams of total estrogen in each gram of cream, split 80% to estriol and 20% to estradiol.
The Bi-Est ratio table
Calculated by The HRT Index. Ratios below are estriol:estradiol, and amounts are per gram of cream—not per day.
| Total concentration | 80/20 estriol | 80/20 estradiol | 50/50 estriol | 50/50 estradiol | Estradiol difference |
|---|---|---|---|---|---|
| 2.5 mg/g | 2.00 mg/g | 0.50 mg/g | 1.25 mg/g | 1.25 mg/g | 2.5× |
| 4 mg/g | 3.20 mg/g | 0.80 mg/g | 2.00 mg/g | 2.00 mg/g | 2.5× |
| 5 mg/g | 4.00 mg/g | 1.00 mg/g | 2.50 mg/g | 2.50 mg/g | 2.5× |
| 10 mg/g | 8.00 mg/g | 2.00 mg/g | 5.00 mg/g | 5.00 mg/g | 2.5× |
The multiplier is constant only when the total concentration and ingredient order are the same.
At 2.5 mg/g, one gram of an 80/20 E3:E2 cream contains 0.5 mg estradiol; one gram of a 50/50 cream contains 1.25 mg. That is per gram. The amount applied per day still depends on the prescription and dispenser.
Is 50/50 stronger than 80/20?
At the same total concentration, delivered amount, and E3:E2 order, 50/50 contains more estradiol. That is arithmetic.
It does not automatically work better. A 1 mg 50/50 formula contains less estradiol than a 5 mg 80/20 formula. And the amount placed on skin is not the amount absorbed into blood.
Four things the ratio table cannot tell you
- 1. Placed is not absorbed. The table calculates contents, not pharmacokinetics.
- 2. A patch's mg/day and a cream's mg/g are different units. One is a delivery rate; the other is a concentration.
- 3. More printed milligrams do not guarantee proportionally greater exposure. Formula, base, site, dispenser, and individual absorption matter.
- 4. The table does not identify your correct treatment or dose. It lets you check the label and ask a precise question.
Bi-Est label decoder
Use this worksheet with the dispensing label—not the seller's marketing page.
- 1. Ingredient order: E3:E2, E2:E3, or not stated.
- 2. Ratio: 80/20, 50/50, or custom.
- 3. Total concentration: ___ mg/g or ___ mg/mL.
- 4. Dispenser output: ___ g, mL, mg, pumps, or clicks per prescribed application.
- 5. Prescribed applications: ___ per day or week.
- 6. Route: body skin, vaginal, or other.
When the label clearly states E3:E2, multiply the total estrogen amount by the ratio fraction:
- Estriol amount = total amount × estriol fraction
- Estradiol amount = total amount × estradiol fraction
If the ingredient order, concentration, or dispenser output is missing, stop. The correct output is not a guessed number. It is:
“Not enough information to calculate—ask the dispensing pharmacist.”
This decoder does not convert Bi-Est to a patch, recommend a dose, or tell you to start, stop, or change medication.
5. How much Bi-Est cream do you use, and how do you know your actual dose?
There is no universal Bi-Est application schedule, dispenser output, or “best” body site. Your prescribed amount comes from the dispensing label. To understand it, you need the concentration, the amount delivered by one pump or click, the number of pumps or clicks, the ratio, and the instructed route.
“Two pumps” is not a dose
A pump is hardware, not a unit of medicine. Two pumps of one cream can deliver a different volume from two pumps of another.
Compounding pharmacies may use a metered pump, click dispenser, syringe, packet, or measured vaginal applicator. The critical question is:
“How many grams or milliliters—and therefore how many milligrams of each hormone—does one prescribed application deliver?”
If the label gives concentration but not dispenser output, call the pharmacy. Do not reverse-engineer it from bottle size.
Where you put it is part of the prescription
The prescribed route and application site are not interchangeable details. Formulation base, skin site, surface area, vaginal use, and frequency can change exposure.
Follow the dispensing label. We are deliberately not naming one “maximum absorption” location because no universal instruction applies across custom formulations.
Transfer precautions belong to the exact formulation
Topical hormones can create contact-transfer concerns. FDA-approved gels and sprays have product-specific drying, handwashing, covering, and contact instructions because those formulations were tested. (FDA-approved estradiol gel labeling)
A compounded cream does not inherit those exact instructions automatically. Ask the dispensing pharmacy:
- How long should the site dry?
- Should it be covered?
- When is skin-to-skin contact safe?
- What should you do around children, partners, and pets?
- What should you do if someone else touches the application site?
The line worth remembering
The dispensing label outranks the marketing page. The website may describe a category. The pharmacy label describes what was prepared for you. If they conflict—or the label is incomplete—call the pharmacy before using it.
6. Does Bi-Est cream actually work for menopause symptoms?
Systemic estrogen is an effective treatment for hot flashes and night sweats in appropriate candidates. That general evidence does not prove every custom Bi-Est formula works predictably. The main randomized Bi-Est study was a 16-day pharmacokinetic trial: two tested cream strengths produced lower estradiol exposure than a standard patch, while the highest tested strength was not statistically different. (Sood et al.; The Menopause Society)
That is not “Bi-Est does nothing.” It is also not proof of superiority, equivalence, or predictable absorption.
What the randomized trial actually tested
Sood and colleagues randomized 40 postmenopausal women to four groups. Three groups used an 80:20 estriol:estradiol cream at total daily amounts of 2.0 mg, 2.5 mg, or 3.0 mg. The comparison group used a Vivelle-Dot 0.05 mg/day estradiol patch. The study lasted 16 days and measured hormone concentrations over time. Approximately 7 to 10 women were analyzed in each arm. (PubMed)
The trial was about pharmacokinetics—what reached the blood and when. It was not a large symptom-relief trial and did not measure long-term clinical outcomes.
What it found
- At steady state, estradiol exposure was lower in the 2.0 mg and 2.5 mg cream groups than in the patch group.
- The 3.0 mg cream group was not statistically different from the patch group for the primary estradiol-exposure comparison.
- Concentrations varied substantially between participants using the compounded creams.
- The results came from one cream base and one short study; they cannot represent every pharmacy's formula.
What the estriol assay did not prove
Do not use this study to claim that an estriol-free patch produced more estriol than an 80%-estriol cream. The estriol measurements were limited and many values were below the assay's detection range. The defensible finding is the estradiol-exposure result above—not a dramatic “estriol inversion.”
The damaging admission survives because the real finding is damaging enough:
The only randomized Bi-Est pharmacokinetic trial did not show that adding estriol produced a clearly superior or reliably equivalent systemic delivery profile.
The 2023 study that points in the same direction—but is not a Bi-Est trial
A 2023 retrospective study examined dried urinary estrogen measures from 1,062 women using transdermal estradiol: compounded estradiol cream, FDA-approved patches, or FDA-approved gels. The compounded-cream group showed lower estrogen exposure than the patch and gel groups at comparable labeled dose categories. (Newman et al.)
That study matters, but keep the boundaries clear:
- It studied compounded estradiol creams, not specifically estriol-plus-estradiol Bi-Est.
- It was retrospective, not randomized.
- It used urinary estrogen metabolites rather than a head-to-head serum pharmacokinetic protocol.
- It cannot tell you what one particular pharmacy's Bi-Est formula will do.
What the evidence can and cannot support
| Claim | Evidence status |
|---|---|
| Systemic estrogen can reduce vasomotor symptoms | Well established for approved hormone therapy |
| A custom Bi-Est formula may produce systemic hormone exposure | Plausible and observed in limited pharmacokinetic data |
| Every Bi-Est cream absorbs consistently | Not established |
| Bi-Est is equivalent to an estradiol patch | Not established |
| Adding estriol makes therapy safer | Not established |
| A printed cream dose can be converted directly to a patch dose | No validated universal conversion |
| Bi-Est is superior to FDA-approved estradiol | Not established |
Plenty of women report feeling better on compounded therapy. A personal response can be real without proving that a product category is more predictable, safer, or superior.
7. Can saliva or blood testing determine the right Bi-Est dose?
Routine saliva or urine testing cannot establish an ideal Bi-Est dose. The Endocrine Society says claims that saliva testing can customize hormone therapy lack scientific support for assay quality, standardization, and clinical correlation. The Menopause Society also calls salivary and urine testing for dosing unreliable. (Endocrine Society; The Menopause Society)
This section may save you a few hundred dollars.
“Personalized dosing based on your levels” sounds precise. For ordinary menopause hormone therapy, dosing is usually guided by symptom response, adverse effects, clinical history, and the treatment goal—not by chasing a universal target number.
There are legitimate reasons a clinician may order blood testing. A test can help investigate another diagnosis, clarify an unusual response, or answer a specific clinical question. That is different from selling a broad “balance panel” as the machine that calculates a custom ratio.
Ask one question before paying:
“What treatment decision will change because of this result?”
If the answer is vague, you may be buying data instead of care.
8. Is Bi-Est cream systemic, local, or both?
“Cream” describes a dosage form, not where the treatment works. A body cream prescribed for hot flashes is intended for systemic exposure. FDA-approved low-dose vaginal estrogen is a separate local treatment for genitourinary symptoms. A custom vaginal Bi-Est formula should not be assumed equivalent to either one. (The Menopause Society)
This is one of the easiest ways to buy the wrong treatment category.
| Your main symptom pattern | Ask about this path first |
|---|---|
| Hot flashes or night sweats, with or without broader menopause symptoms | Systemic options: FDA-approved patch, gel, spray, tablet, or—when a documented need exists—a compounded body formula |
| Vaginal dryness, burning, pain with sex, urinary urgency, or recurrent local symptoms without hot flashes | Local GSM treatment, including FDA-approved low-dose vaginal options |
| Both systemic and local symptoms | A clinician may consider a systemic plan, a local plan, or both based on your history |
| Symptoms are unclear, changing, or accompanied by bleeding or pain | A broader clinical assessment before choosing a product |
Low-dose vaginal estrogen is not a weak version of systemic treatment. It is designed for a different job, and very little generally reaches systemic circulation at low doses. It does not treat hot flashes. Read the vaginal estrogen guide →
Can Bi-Est be prescribed for vaginal use?
Yes. A prescriber can order a compounded vaginal estriol-and-estradiol formula. That does not make it an FDA-approved low-dose vaginal estrogen product, and it does not make body and vaginal directions interchangeable.
Never change the route on your own. Do not put a body cream vaginally or use a vaginal formula on body skin because a seller, forum post, or friend suggested it. Route is part of the prescription.
Does your symptom pattern point to systemic, local, or in-person care? Get your personalized HRT path before choosing a product.
9. Should you use compounded Bi-Est at all?
The major authorities do not use identical wording, but they converge on one rule: compounded menopausal hormone therapy should not be the routine default when an FDA-approved product can meet the patient's need. The narrowest evidence-based lane is a documented problem an approved product cannot solve—not a preference for “natural,” “gentler,” or “more personalized” marketing.
Here is what each source actually says.
| Authority | Current position | The practical gate |
|---|---|---|
| National Academies | Recommends restricting compounded bioidentical hormone therapy to patients with a documented allergy to an ingredient in an approved product or a documented need for a dosage form not commercially available | Document the unmet need before compounding (National Academies) |
| The Menopause Society | Says compounded products raise concerns about regulation, dosing, purity, sterility, efficacy and safety data, and risk labeling; patient preference alone should not justify use | Use an approved product when it can meet the need (2022 position statement) |
| ACOG | Says compounded bioidentical menopausal hormone therapy should not be prescribed routinely when FDA-approved formulations exist | Counsel clearly on lack of approval and compounding-specific risks (ACOG) |
| Endocrine Society | Says there is little or no evidence supporting claims that compounded therapy is safer or more effective than approved products | Do not treat “customized” as proof of benefit (Endocrine Society) |
| FDA | Says compounded drugs are not FDA-approved and no approved U.S. drug contains estriol | Do not blur ingredient sourcing with finished-product approval (FDA) |
Are you inside the legitimate compounding lane?
The clearest reasons are:
- A documented allergy or reaction to an active or inactive ingredient in available approved products.
- A medically necessary dosage form that is not commercially available.
- Another patient-specific need a licensed prescriber can explain in writing and cannot meet with an approved product.
You are not automatically inside that lane because:
- A seller called Bi-Est natural or bioidentical.
- A saliva test produced a number.
- You prefer a custom ratio without a documented clinical reason.
- A product page says estriol is gentler or safer.
- An approved patch caused one problem before anyone considered another approved route, brand, gel, spray, tablet, or local option.
If you are inside it, here is your permission
The internet is not kind to women who use compounded hormones. You may have been told you were foolish, gullible, or doing something illegitimate.
If a clinician documented a real problem an approved product cannot solve, you are not being difficult and you have not fallen for anything. Compounding exists for patient-specific needs. The point is not to shame the category. The point is to make the custom part earn its place.
If you are outside it, that is not a downgrade
FDA-approved estradiol can still be bioidentical. Choosing a measured, labeled product is not choosing something less natural. It is choosing a product with standardized manufacturing, reviewed labeling, and a defined delivery system.
Still not sure which side of the line you are on? Use Find My HRT Path to match the medication model to your symptoms, uterus status, state, and payment method.
10. What does Bi-Est cream cost in 2026?
The advertised medication price is not enough to compare Bi-Est programs. Current public figures run from $51 a month at a program that is not accepting new patients to $249 a month on one provider FAQ, while other pages use lower prepaid-term rates. Billing cadence, labs, intake fees, state access, and cancellation terms change the real cost.
Here is the number that matters: what leaves your account before you have received 90 days of care. A $64 “member price” is not a $64 program when the membership is another $99. An $89 “monthly” product is not billed twelve times a year when the company processes it every 28 days.
The Bi-Est Disclosure Ledger
Provider-stated public information checked August 31, 2026. Ratios are shown as estriol:estradiol. “Not published” means we did not find the field on the public page; it does not mean the provider will not disclose it during intake.
| Seller | Formula details published | Current public price | Care, labs, and billing | State/access status | Material fact to verify before paying |
|---|---|---|---|---|---|
| Winona | 50/50; public page does not show mg/g, container size, or milligrams per pump | $89 per 30-day supply | No separate membership; physician review, messaging, and shipping included; orders process every 28 days | Public state list covers 37 states plus Puerto Rico; the FAQ says most patients are ages 35–59 | Exact concentration, dispenser output, prescribed route, and whether your next order can still be stopped (Winona; state and age rules; billing) |
| Therisse | 80/20; starter strength published as 2.5 mg/g | $51/month for one therapy, billed $153 quarterly; annual plan as low as $44/month | No consult fee; shipping included; HSA/FSA accepted | Licensed in 50 states, but the live intake currently says not accepting new patients | Do not treat the displayed price as an available option until intake reopens (Therisse cream; pricing; current intake) |
| Hone Health | 50/50 or 80/20; public product page does not show the final prescribed concentration | $80/month medication + $155/month Premium membership = $235/month recurring | Initial diagnostics currently shown at $65; Premium is the tier that includes prescription treatment access | Women's care is available only in the states shown during intake | Hone's official pages currently conflict: one says cancellation is immediate, while the membership FAQ and payment consent say it takes effect at the end of the current billing period. Confirm which rule applies before enrolling (Hone Bi-Est; Hone membership; billing page; membership FAQ) |
| Healthspan | 50/50; public page does not show the final prescribed concentration | $80/month, or $64/month member price + $99/month membership = $163/month in recurring components | Medication page shows the member medication billed as $192 quarterly; membership includes baseline and follow-up labs, clinician review, and support | Public women's program currently lists availability in 42 states | Confirm the exact first-90-day billing sequence and cancellation terms before checkout (Healthspan Bi-Est; women's program) |
| AgeMD | 80/20 at 2.5, 4, 5, or 10 mg/g | Product page: $224/month for 3 months, $204/month for 6 months, or $149/month for 12 months, each billed upfront for the term | Product page says the figures are effective monthly rates; a separate FAQ describes a $199 intake and a $249/month program, so the public pages do not reconcile cleanly | Eligibility and licensure are determined during intake | Get the exact upfront amount, intake charge, included labs, refill term, and refund rules in writing (AgeMD product page; AgeMD FAQ) |
| Empower Pharmacy | 50/50 or 80/20; 1–10 mg/mL; 30 mL | No public patient price | A 503A pharmacy product supplied pursuant to an individualized prescription; not an integrated telehealth program | Shipping depends on pharmacy licensure and the prescriber's state | Prescriber fee, dispensing price, cream base, amount per pump, and state shipping (Empower) |
| BIOLabs PRO / Shyne Brands OTC label | Label presents 80:20 and conflicting denominator information in the same public record | Retail price is not used in this comparison | Nonprescription product listed as an unapproved OTC drug; not patient-specific compounding | Retail availability varies | This is not a cheaper version of prescription-compounded Bi-Est (DailyMed) |
What the ledger shows that a price list does not
The cheapest published program is currently unavailable to new patients. Therisse's $51 figure is real, but its live intake is closed. That makes it a useful benchmark, not an actionable recommendation.
The largest price trap is the separate membership. Hone's $80 cream becomes $235 in recurring monthly charges when the required Premium membership is included. Healthspan's $64 member medication price becomes $163 when its $99 membership is added.
The largest disclosure gap is still the dose. Winona publishes the 50/50 ratio and the $89 price, but not the mg/g concentration, container size, or amount delivered per pump. AgeMD and Empower publish more formula detail, but AgeMD's public pricing pages conflict and Empower does not publish a patient price.
The 28-day billing detail changes Winona's annual cost
Winona describes a 30-day supply that is processed every 28 days. That creates about 13.04 billing cycles in 365 days, not 12.
At $89 per cycle:
- 12 charges = $1,068.
- 13.04 charges = about $1,160.18 per year.
- Averaged across twelve calendar months, that is about $96.68 per month.
That does not make the program deceptive; the refill interval is publicly stated. It does mean “$89 a month” is not the number to use for an annual budget.
Does insurance cover Bi-Est cream?
Most telehealth Bi-Est programs we checked are cash-pay and do not directly bill medical or pharmacy insurance for the compounded cream. A local plan may reimburse part of a prescribed compound, but coverage depends on the plan, ingredient, pharmacy, and benefit rules. Do not treat “HSA/FSA accepted” as a promise that your administrator will approve the expense.
Ask for four answers before checkout:
- 1. Does the provider bill insurance, or only give you a receipt?
- 2. Is the medication itself submitted to a pharmacy benefit?
- 3. Are the visit, membership, labs, and medication separate charges?
- 4. What happens financially if the clinician decides not to prescribe?
A clinician has already documented why you need compounded Bi-Est? Winona is the clearest currently available affiliate option in this dataset: a published 50/50 formula, $89 per 30-day supply, no separate membership, and an FDA-approved estradiol lane if the clinician decides compounding is not the right fit. See Winona's current Bi-Est price and check eligibility (sponsored link; The HRT Index may earn a commission).
11. Where can you get legitimate Bi-Est cream, and what should you check first?
A legitimate prescription Bi-Est path requires a licensed prescriber, a patient-specific prescription, and a compounding pharmacy authorized to dispense to your state. You can use your own clinician and pharmacy or an integrated telehealth program. A nonprescription cream carrying the same name is not the same route, even when its packaging looks clinical.
Route 1: Your own clinician plus a compounding pharmacy
This route can avoid a telehealth membership and gives you more freedom to compare pharmacies. It is not automatically the cheapest: the office visit, testing, dispensing price, shipping, and follow-up still matter.
Best for: women who already have a clinician willing to document why compounding is needed and who want to choose the pharmacy.
Route 2: An integrated telehealth program
The program bundles the prescriber, asynchronous or scheduled care, pharmacy, shipping, and follow-up. The convenience is real. So is the possibility that the advertised cream price omits a membership or intake fee.
Best for: women who do not have a prescriber, want one system to handle the process, and live in a state the program serves.
Route 3: The one to reject as an equivalent substitute
A nonprescription “BiEST” product is not patient-specific 503A compounding. If a licensed clinician does not review you and issue a prescription, it is a different regulatory category—not a cheaper version of the same treatment.
One thing you should know about Winona before you click anything
We link to Winona and may earn a commission. So here is the missing number we would rather you heard from us.
Winona does not publish its Bi-Est cream's mg/g concentration, container size, or milligrams delivered per pump. It publishes the 50/50 ratio and the $89 price, which is more disclosure than several sellers provide, but you still cannot run the dose arithmetic before a prescription is written.
If seeing the concentration before you pay is your priority, AgeMD publishes four possible strengths and Empower publishes its pharmacy range. Therisse publishes a starter strength, but it is not accepting new patients right now. We earn nothing from those alternatives.
Here is why Winona can still fit the right reader. It does not add a separate membership fee, its clinician reviews the intake before the order is finalized, and its catalog includes FDA-approved estradiol options. A reader who learns during the consultation that she does not need compounding does not have to force the Bi-Est choice to stay inside the same care system.
The second Winona fact that cannot be softened
Winona's current body-cream page says estradiol and estriol are FDA-approved active ingredients. FDA says no approved U.S. drug contains estriol. Winona labels the final product as compounded elsewhere on the page, but the ingredient-approval sentence is still wrong.
That does not prove the program is illegitimate. It does mean the reader should not rely on that sentence to evaluate regulatory status.
The twelve questions to ask before you pay
Copy these into a message. A provider should be able to answer them without making you feel difficult.
- 1. Which hormone comes first in the ratio—estriol or estradiol?
- 2. What is the total concentration, in mg/g or mg/mL?
- 3. How much does one pump or click deliver, in grams or milliliters?
- 4. How many milligrams of estriol and estradiol are in the prescribed application?
- 5. What route is this exact formula prepared for—body skin, vaginal use, or another route?
- 6. Why is this compound being chosen instead of an FDA-approved estradiol patch, gel, spray, tablet, or vaginal product?
- 7. Which pharmacy prepares it, and is that pharmacy licensed to dispense to my state?
- 8. If I have a uterus, what exact progestogen plan protects the endometrium?
- 9. What symptoms and adverse effects are we monitoring?
- 10. When is follow-up, and what would trigger a formula change?
- 11. What is my first-90-day total, including intake, membership, labs, medication, shipping, and refill timing?
- 12. How do I stop the next order, and when does the order become nonrefundable?
Pick the door that matches the decision you have actually made:
- I have a documented reason for compounded Bi-Est—check Winona eligibility (sponsored link; The HRT Index may earn a commission).
- I want an FDA-approved estradiol option—compare online menopause providers
- I want to use insurance—check Midi's coverage and self-pay rules (sponsored link; The HRT Index may earn a commission).
12. Do you need progesterone with Bi-Est cream if you have a uterus?
If you have a uterus and Bi-Est is being used systemically, the plan needs adequate progestogen to protect the endometrium. Do not assume that progesterone mixed into a skin cream provides proven protection. Current guidance says transdermal compounded progesterone has variable absorption and may not protect the lining adequately. (British Menopause Society; Stute 2016)
This is the most important section on the page.
Why it matters
Systemic estrogen stimulates the endometrium. In a person with a uterus, unopposed systemic estrogen raises the risk of endometrial hyperplasia and cancer. An evidence-supported progestogen regimen is used to oppose that stimulation.
The word “progesterone” on a cream label does not establish that the route, dose, and schedule have been shown to protect the endometrium.
What the current evidence says about progesterone cream
The British Menopause Society's May 2026 clinician tool states that compounded transdermal progesterone creams and gels can have variable absorption and may not provide sufficient endometrial protection. A systematic review by Stute and colleagues reached the direct conclusion that transdermal micronized progesterone does not provide endometrial protection.
Winona's combined-cream page makes the opposite commercial claim: that its topical progesterone provides uterine protection. That is a provider statement, not a substitute for evidence on the exact formula and regimen. (Winona combined cream)
The practical conclusion is not “the evidence is evenly divided.” It is:
If your only progestogen is in a skin cream, ask what evidence supports that exact route, amount, and schedule for endometrial protection. Do not assume protection because progesterone is present.
Do not stop a prescribed progestogen because of this page
If progesterone is causing side effects, talk with the prescriber about route, schedule, formulation, and alternatives. Do not remove the progestogen from a systemic-estrogen plan on your own.
“No uterus” means no uterus
- Endometrial ablation is not a hysterectomy. The uterus remains, and residual endometrium can remain behind scarring.
- A supracervical hysterectomy removes the uterine body but leaves the cervix; ask what tissue remains and what your clinician recommends.
- Not having periods does not establish that the uterus was removed.
When the surgical history is unclear, get the operative report rather than guessing.
The question to send your clinician
“I have a uterus and I am using systemic compounded estrogen. What exact progestogen formulation, route, dose, and schedule is protecting my endometrium, and what evidence supports it?”
Postmenopausal bleeding is not an adjustment to watch online
Any bleeding after menopause needs prompt clinical evaluation. Contact a clinician who can arrange the appropriate examination and testing. Do not let a product page normalize it as routine “hormone balancing.”
13. What are Bi-Est cream's side effects and risks?
Bi-Est can produce estrogen-related adverse effects while adding uncertainty from a nonstandard compounded formula. Breast tenderness, headache, nausea, bloating, spotting, and skin irritation can occur, but there is no single FDA-approved Bi-Est label that defines one complete adverse-effect, contraindication, interaction, and transfer profile for every custom cream. (FDA-approved estradiol gel labeling)
Possible estrogen-related effects
Depending on the formula, exposure, and individual response, a clinician may hear reports of:
- Breast tenderness.
- Headache.
- Nausea.
- Bloating or fluid retention.
- Spotting or bleeding.
- Mood changes.
- Skin irritation at the application site.
Those symptoms are not proof that the dose is too high, too low, or “imbalanced.” They are reasons to contact the prescriber or pharmacist rather than changing the amount yourself.
The risk-label gap is real
FDA-approved estradiol products come with standardized prescribing information, contraindications, warnings, interactions, patient instructions, manufacturing specifications, and adverse-event reporting language.
A patient-specific compounded cream does not have one FDA-reviewed product label. It comes with a pharmacy label and instructions for that prescription. That makes the prescriber and dispensing pharmacist more—not less—important.
Contact the prescriber or pharmacist when:
- The label does not clearly state ingredients, concentration, route, or delivered amount.
- The pump, clicker, texture, color, smell, or dispensing behavior changes between refills.
- Side effects are significant, new, or persistent.
- Symptoms are not improving on the agreed follow-up timeline.
- You are switching pharmacies, ratios, strengths, bases, or routes.
- You miss doses and do not know what the pharmacy instructions require.
- You develop any unexpected bleeding.
Seek urgent medical care for symptoms that could indicate a clot, stroke, or cardiac event, including sudden chest pain, severe shortness of breath, one-sided weakness, difficulty speaking, or a suddenly swollen painful leg.
Transfer precautions cannot be copied from one cream to every cream
Topical estrogen can transfer through direct skin contact. Wash your hands and follow the exact pharmacy instructions about drying time, covered skin, bathing, and contact with children, partners, or pets. Do not invent a universal waiting period from another product's label.
14. Who should start somewhere other than an online Bi-Est program?
A product-first telehealth intake is the wrong starting point when the immediate question is diagnosis, bleeding, cancer-specific risk, a possible clot or cardiovascular event, pregnancy, or another issue requiring examination or urgent testing. Age over 60 or being more than 10 years past menopause changes the benefit-risk discussion; it is not an automatic universal ban. (The Menopause Society)
We would rather lose the provider click than route the wrong person into a product funnel.
| If this sounds like you | Start here instead |
|---|---|
| Any unexplained bleeding after menopause | Prompt in-person evaluation before choosing a hormone product |
| Personal history of breast, uterine, or another estrogen-sensitive cancer | The clinician managing that history, with menopause expertise where available |
| Current symptoms that could represent a clot, stroke, or heart problem | Urgent or emergency care—not an online HRT intake |
| Significant liver disease or a complex medication history | A clinician who can review records, interactions, and alternatives |
| Pregnant, possibly pregnant, or breastfeeding | A clinician; do not start this product path |
| Only vaginal or urinary menopause symptoms | The local vaginal estrogen decision guide |
| A patch caused adhesive irritation | Ask about another approved patch brand, gel, or spray before assuming compounding is required |
| Insurance is the priority | An insurance-based menopause provider or your own clinician and retail pharmacy |
| You are over 60 or more than 10 years beyond menopause onset | Individual benefit-risk assessment rather than an automatic online recommendation |
| You do not know whether you still have a uterus | Confirm the surgical history before deciding on the progestogen plan |
This is not a complete contraindication list. It is a routing map for the situations a general page cannot safely resolve.
15. Bi-Est cream vs an FDA-approved patch, gel, or vaginal estrogen
FDA-approved estradiol products deliver a standardized dose through a defined system with reviewed labeling. Bi-Est combines two estrogens in a custom preparation whose formula and absorption can vary. The real decision is not “natural versus pharmaceutical”—both lanes can use bioidentical hormones. It is standardized versus custom, and custom must solve a real problem.
| Decision factor | Compounded Bi-Est body cream | FDA-approved estradiol patch | FDA-approved estradiol gel or spray | FDA-approved low-dose vaginal estrogen |
|---|---|---|---|---|
| Primary ingredient(s) | Estriol + estradiol | Estradiol | Estradiol | Product-specific estrogen |
| Finished product FDA-approved? | No | Yes | Yes | Yes |
| Main treatment scope | Usually systemic when prescribed as body cream | Systemic | Systemic | Local vaginal/urinary symptoms |
| What the printed number means | Usually concentration; daily amount also requires dispenser output and prescribed quantity | Product-specific delivery rate | Product-specific pump, packet, or spray dose | Product-specific insert, ring, tablet, or cream dose |
| Manufacturing and labeling | Pharmacy- and prescription-specific | Standardized and FDA-reviewed | Standardized and FDA-reviewed | Standardized and FDA-reviewed |
| Insurance potential | Often cash-pay and plan-specific | Often possible, plan-specific | Often possible, plan-specific | Often possible, plan-specific |
| Best reason to discuss it | A documented need an approved option cannot meet | Approved systemic delivery without daily cream | Approved transdermal option when adhesive or patch preference is a problem | Direct local treatment when systemic symptoms are not the target |
| Main limitation | Limited product-specific evidence, variable formula disclosure, no universal conversion | Adhesive, product availability, and wear issues can matter | Daily-use and transfer instructions | Does not treat hot flashes |
The reframe that settles the “bioidentical” question
Estradiol in an approved patch, gel, spray, or tablet is bioidentical. Micronized progesterone is bioidentical. Choosing an FDA-approved product does not mean choosing a synthetic imitation of your body's hormone.
You are choosing between standardized and custom. Custom is useful when the custom feature solves a documented problem. It is not automatically an upgrade.
If a patch is the problem, the next step is not automatically Bi-Est
A patch can fail because of adhesive, skin reaction, wear, availability, price, or preference. An FDA-approved gel or spray may preserve the approved transdermal lane without the adhesive. A different patch brand may use a different delivery system. Ask those questions before accepting “compounded” as the only alternative.
The insurance-first provider path
Midi provides menopause care in all 50 states and is in-network with many commercial PPO plans. Its published self-pay price is $250 for the initial visit and $150 for follow-up visits. Midi does not bill Medicare, but Medicare beneficiaries can use its self-pay option. Midi cannot treat Medicaid patients, including as self-pay. Medication costs are separate and depend on the prescription and pharmacy benefit. (Midi pricing; Midi insurance)
Want the FDA-approved lane with an insurance check before the visit? Check Midi's coverage and self-pay rules (sponsored link; The HRT Index may earn a commission).
16. What did The HRT Index verify—and what still requires intake or checkout?
Every commercial row on this page was rechecked against a current provider, pharmacy, regulatory, or labeling source on August 31, 2026. “Verified” means the cited public source supports the stated fact. It does not mean we purchased treatment, tested medication, inspected a pharmacy, or confirmed the reader's individual eligibility.
Verified publicly
- FDA's statement that no approved U.S. drug contains estriol.
- The distinction between FDA approval and patient-specific compounding.
- The DailyMed OTC BiEST record, its unapproved status, and its internal denominator conflict.
- The Sood trial's design and estradiol-exposure result.
- The scope and limitations of the Newman compounded-estradiol analysis.
- Current society positions on compounded hormone therapy, saliva testing, and transdermal progesterone.
- The provider prices, ratios, published strengths, memberships, and state claims shown in the ledger.
Not independently verified
- The physical hormone content of any tube.
- Lot-to-lot potency or uniformity.
- The final dose a clinician would prescribe.
- A provider's actual response time for a particular patient.
- Eligibility before a licensed clinician reviews the history.
- State access when a public list and intake system differ.
- Charges that appear only after a personalized checkout.
- Whether an HSA, FSA, insurance plan, Medicare drug plan, or employer plan will reimburse a specific claim.
Refresh schedule
| Element | Recheck cadence | Trigger for an immediate update |
|---|---|---|
| Provider prices, memberships, billing intervals, state access, and formula disclosures | Monthly for featured providers; quarterly for the full ledger | Checkout, formulary, state, pharmacy, or policy change |
| FDA estriol and compounding status | Monthly monitoring | FDA rule, approval, warning, enforcement action, or advisory committee change |
| Medical-society guidance | Semiannual | New position statement, guideline, or safety communication |
| Clinical evidence | Semiannual | New trial, systematic review, or guideline |
| DailyMed OTC BiEST records | Quarterly | Label revision, delisting, new NDC, or new enforcement information |
| Internal links and offer disclosures | Monthly crawl | Redirect, broken link, affiliate-status change, or page-policy change |
| Find My HRT Path privacy behavior | Every deployment | Form, analytics, storage, or consent change |
The visible Last verified date should change only after a real verification pass—not because a template or build process ran.
Found an error or a page that changed? Email partners@thehrtindex.com. Corrections should be dated and visible.
What real customers can—and cannot—tell you
A customer review can tell you whether a company answered messages, shipped reliably, or made the process easy. It cannot prove the cream's dose, absorption, safety, or effectiveness. Those are evidence and labeling questions, not testimonial questions.
A recent verified Winona reviewer wrote:
“My provider was fast to respond with clear information.”
— Tracy, verified Trustpilot review, August 16, 2026 (source)
This quote describes service, not medical safety or effectiveness. Individual experiences vary. The HRT Index may earn a commission from Winona.
The same current review pool includes complaints about delayed responses and interrupted prescriptions. That balance matters more than the aggregate star number, which is why this page does not publish a provider rating or AggregateRating schema.
Frequently asked questions about Biest cream for menopause
Is Biest cream FDA-approved?
No. The finished compounded cream is not FDA-approved, and FDA says no approved U.S. drug contains estriol. A patient-specific product can be lawfully compounded when the applicable federal and state conditions are met, but FDA does not preapprove the finished formula.
What does Bi-Est 80/20 mean?
It commonly means 80% estriol and 20% estradiol, written E3:E2. The label must identify the ingredient order. “80/20” without names is not enough to calculate anything safely.
Is Bi-Est 50/50 stronger than 80/20?
At the same total concentration and with the same E3:E2 ordering, 50/50 contains 2.5 times as much estradiol per gram as 80/20. That does not prove stronger absorption, greater symptom relief, or a better formula.
Can you buy Biest cream over the counter?
Prescription-compounded Bi-Est requires a prescription. Nonprescription products are sold under similar names, but the DailyMed example checked on this page is listed as an unapproved OTC drug and is not the same regulatory category.
Is estriol safer than estradiol?
No comparative safety advantage has been established. FDA says it does not have evidence that estriol-containing drugs are safe and effective or safer forms of estrogen. “Less potent” is not the same claim as “lower risk.”
Does Bi-Est cream work for hot flashes?
Systemic estrogen is an effective treatment for vasomotor symptoms in appropriate candidates. Direct Bi-Est evidence is limited. The randomized pharmacokinetic trial showed lower estradiol exposure at two tested cream doses than with the comparison patch and did not establish symptom superiority or long-term safety.
How long does Bi-Est cream take to work?
There is no universal timeline for a custom formula. The answer depends on the symptom, formula, exposure, adherence, and individual response. Agree on a follow-up point with the prescriber rather than accepting a guaranteed timeline from a product page.
Where should Bi-Est cream be applied?
Only to the site and by the route on the dispensing label. Custom bases and prescriptions differ. There is no universal “best absorption spot” that can safely replace the pharmacy instructions.
Can Bi-Est cream transfer to another person?
Topical estrogen can transfer through direct skin contact. Follow the pharmacy's instructions about handwashing, drying, covering the site, bathing, and contact with children, partners, and pets.
Do you need progesterone with Bi-Est?
If you have a uterus and the Bi-Est is systemic, the plan needs adequate progestogen to protect the endometrium. The exact route, amount, and schedule matter.
Is progesterone mixed into a skin cream enough?
Do not assume it is. The British Menopause Society says compounded transdermal progesterone may not provide sufficient endometrial protection, and a systematic review concluded that transdermal micronized progesterone does not provide endometrial protection.
Does insurance cover Bi-Est cream?
Sometimes, but most direct-to-consumer Bi-Est programs we checked are cash-pay. Coverage depends on the plan, pharmacy, ingredients, and benefit rules. HSA/FSA card acceptance is not a reimbursement guarantee.
How much does Bi-Est cream cost per month?
The current public market cannot be summarized by one number. Therisse lists $51 a month but is not accepting new patients. Winona lists $89 every 28 days. Healthspan's member components total $163 a month. Hone's required medication and Premium membership total $235 a month. AgeMD's public pages show different figures depending on the page and prepaid term.
Is Bi-Est cream the same as vaginal estrogen?
No. A body cream intended for systemic exposure and an FDA-approved low-dose vaginal product have different treatment goals, evidence, dosing, and expected systemic absorption.
Can saliva testing determine the right Bi-Est dose?
No reliable routine target has been established for saliva-guided menopause dosing. Ask what treatment decision a test result will change before paying for the test.
What patch dose equals a Bi-Est cream dose?
There is no validated universal conversion. A patch label usually states a delivery rate; a cream label states concentration. Exposure also depends on the formula, amount applied, base, route, and individual absorption.
What is the difference between Bi-Est and Tri-Est?
Bi-Est contains estriol and estradiol. Tri-Est adds estrone. In the U.S., both are compounded preparations rather than standardized FDA-approved drug products.
Can Bi-Est cream cause weight gain?
Estrogen-related bloating or fluid retention can affect how weight feels or changes temporarily. There is no solid evidence that Bi-Est uniquely causes fat gain, and it should not be sold as a weight-loss product.
Is Bi-Est “natural”?
Estriol and estradiol can be structurally identical to hormones the body produces. That fact does not establish FDA approval, manufacturing consistency, safety, or superiority. FDA-approved estradiol can also be bioidentical.
Is estriol banned in the United States?
No. Estriol is not an FDA-approved drug ingredient in a finished U.S. product, but patient-specific estriol preparations can currently be compounded when applicable legal requirements are met. That is different from FDA approval and different from a ban.
What should you do if you bleed after menopause while using Bi-Est?
Contact a clinician promptly for evaluation. Do not increase, decrease, or stop the hormone solely on the basis of a general article, and do not accept “hormone adjustment” as a substitute for evaluating postmenopausal bleeding.
The bottom line
Biest cream for menopause is real prescription medicine when it is prepared for an individual patient by a legitimate compounding pharmacy. It is not FDA-approved, no FDA-approved U.S. drug contains estriol, and no seller has earned the right to call it safer, gentler, or superior to approved estradiol.
For most women, the evidence-first question is which FDA-approved estradiol route fits the symptoms, uterus status, risk history, insurance, and state.
For the smaller group with a documented need an approved product cannot meet, Bi-Est is a legitimate path. If that is you, you are not being difficult and you have not fallen for anything. Make the formula, pharmacy, uterine-protection plan, total cost, and follow-up visible before you pay.
You should be able to answer three questions without searching again:
- 1. Why do I need the compound?
- 2. What exactly is in my prescribed application?
- 3. What protects me if I have a uterus?
Still not sure which HRT program is right for you? Take our free 60-second matching quiz.
Sources
Regulatory and government
- U.S. Food and Drug Administration: Menopause
- FDA: Compounding and FDA—Questions and Answers
- Electronic Code of Federal Regulations: 21 CFR § 310.530
- DailyMed search for NDC 82018-0030-6
- DailyMed: FDA-approved estradiol gel labeling
Guidelines and position statements
- National Academies: Prescribers should restrict non-FDA-approved compounded bioidentical hormones
- The 2022 hormone therapy position statement of The North American Menopause Society
- The Menopause Society: Hormone Therapy
- ACOG: Compounded Bioidentical Menopausal Hormone Therapy
- Endocrine Society: Compounded Bioidentical Hormone Therapy
- British Menopause Society: Progestogens and endometrial protection
Clinical evidence
- Sood et al. 2013: Bioidentical compounded hormones—pharmacokinetic randomized trial
- Newman et al. 2023: Comparative estrogen exposure from compounded transdermal estradiol creams and FDA-approved patches and gels
- Stute et al. 2016: Micronized progesterone and endometrial protection
Provider and commercial sources checked August 31, 2026
- Winona estrogen body cream
- Winona estrogen body cream with progesterone
- Winona refill timing
- Winona FAQ, state list, age limits, and care model
- Hone Bi-Est cream
- Hone women's membership
- Hone billing and cancellation page
- Hone membership FAQ
- Healthspan Bi-Est cream
- Healthspan women's health program
- Therisse Bi-Est cream
- Therisse pricing and FAQ
- Therisse current intake status
- AgeMD Bi-Est product page
- AgeMD FAQ
- Empower Pharmacy Bi-Est cream
- Midi pricing
- Midi insurance
- Winona customer reviews
This page is educational and is not medical advice. It has not been medically reviewed by a clinician. Hormone therapy has material risks and benefits that depend on the individual history, formulation, route, dose, age, timing, and treatment goal. Talk with a licensed clinician before starting, stopping, switching, or changing any hormone medication.